Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-11 22:37 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
Benralizumab in the Treatment of Patients With Severe Asthma With ABPA
NCT04108962 · Baylor Research Institute · PHASE4 · withdrawn · last registry update 2022-02-01 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “Difficult to find eligible patients willing to participate.” | – | Registry record, Baylor Research Institute |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against IL5RA within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2023-01-20Phase 3 first posted: AstraZeneca, Benralizumab + Placebo (NCT05692180)
- 2022-06-28Results posted on the registry: AstraZeneca, Benralizumab (NCT03557307)
- 2022-02-23Phase 3 first posted: AstraZeneca, Benralizumab + Placebo (NCT05251909)
- 2022-02-08Results posted on the registry: National Institute of Allergy and Infectious Diseases (NIAID), benralizumab (NCT02130882)
- 2021-10-12Results posted on the registry: AstraZeneca, Benralizumab 30 mg SC + Mometasone Furoate + Matching placebo SC + Mometasone Furoate (NCT03401229)
- 2021-08-17Results posted on the registry: Children's Hospital Medical Center, Cincinnati, Benralizumab + Placebo (NCT03473977)
- 2021-08-16Phase 3 first posted: AstraZeneca, Benralizumab + Placebo to Benralizumab (NCT05006573)
- 2021-04-13Results posted on the registry: AstraZeneca, Benralizumab + Benralizumab (NCT02808819)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision